開源控股(01215.HK)2024年扭虧為盈至約3580萬港元
格隆匯3月31日丨開源控股(01215.HK)公吿,截至2024年12月31日止年度,集團收益為約3.235億港元,較去年度增加約10.2%。集團於年度錄得溢利約3580萬港元,而去年度則錄得虧損約240萬港元。年度每股基本及攤薄盈利為0.28港仙,而去年度則錄得每股基本及攤薄虧損0.02港仙。
本年度,收益大幅增加主要由於(其中包括)2024年巴黎奧運會導致酒店經營分部旗下Paris Marriott Hotel Champs-Elysees("Paris Marriott Hotel")貢獻收益增加。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.